reports
- Research Department
IBERIAN DAILY 05 SEPTEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IBERDROLA, INDITEX, TELEFÓNICA. Debt truce and bullish stock markets European stock markets saw new gains, with the Ibex exceeding the 14,900-point barrier and France’s CAC hit by the political uncertainty. In the STOXX 600, Media and Telecommunications were the best-performing sectors whereas Travel&Leisure and Consumer Goods fell the most. On the macro side, in the euro zone, July’s retail sales slowed down more thn expected. In the US, August’s non-manufacturing ISM climbed mor...
- Rafael Bonardell
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
- Martial Descoutures
- Team Pharma
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Martial Descoutures
- Research Department
IBERIAN DAILY 04 SEPTEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IBERDROLA. Calm after the storm European stock markets recovered some ground after Tuesday’s corrections and the widening of bond yields. The Ibex ended its negative performance after sliding -2.5% in 3 sessions. Thus, in the STOXX 600, almost all sectors (16/20) closed with gains, led by Pharma and Retail vs. the worse performance of Energy and Telecommunications. On the macro side, in the euro zone, August’s final services PMI was cut slightly. In Spain, the services PMI fell mo...
- Research Department
INFORME DIARIO 04 SEPTIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA. EUROPA: SANOFI. Calma tras la tormenta Las bolsas europeas recuperaron ayer algo de terreno después de las caídas del martes propiciadas en parte por la venta de bonos soberanos en el tramo ultra largo. Tras corregir un -2,5% en tres sesiones el Ibex cortó su racha negativa para quedarse cerca de los 14.800 puntos. Casi todos los sectores del STOXX (16/20) terminaron con ganancias, lideradas por Farma y Retail frente al peor comportamien...
- Team Pharma
Press Release: Sanofi’s amlitelimab met all primary and key secondary ...
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at Week 24, with efficacy progressively increasing throughout the treatment period Study results reinforce ...
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les crit...
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, administré toutes les quatre semaines ou toutes les douze semaines, a démontré une efficacité statistiquement et cliniquement significative en termes de cla...
Press Release: Sanofi’s amlitelimab met all primary and key secondary ...
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at Week 24, with efficacy progressively increasing throughout the treatment period Study results reinforce ...
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les crit...
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, administré toutes les quatre semaines ou toutes les douze semaines, a démontré une efficacité statistiquement et cliniquement significative en termes de cla...
- Research Department
IBERIAN DAILY 01 SEPTEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IBERDROLA, SANTANDER. Stock markets ended August with gains Last week the main European stock markets closed with drops >-2.0% due to the political doubts in France (a confidence vote could end with the current PM) and renewed trade tensions in the US, China and India. In the STOXX 600, Consumer Goods and Energy led the gains, whereas Banks, Construction and Chemicals recorded the biggest drops. On the macro side, in Germany, July’s retail sales fell more than expected whereas inf...
- Research Department
INFORME DIARIO 01 SEPTIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IBERDROLA, SANTANDER. Las bolsas concluyen el mes de agosto con ganancias La semana pasada las principales bolsas europeas cerraron con pérdidas superiores al -2,0% dadas las dudas políticas en Francia con la moción de confianza que podría acabar con actual Primer Ministro y las renovadas tensiones comerciales entre EE.UU., China e India. En el STOXX 600 los sectores que más subieron fueron Bienes de Consumo y Energía, mientras que Bancos, Construc...
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor ...
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptomsITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life; more than 25,000 US adults could benefit from advanced treatment P...
Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis c...
Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune Ce traitement novateur cible la tyrosine kinase de Bruton (BTK) par une modulation multi-immune pour aider à traiter les causes profondes de la thrombocytopénie immune (TPI)L’approbation se fonde sur l’étude de phase 3 LUNA 3 qui a démontré une réponse plaquettaire rapide et durable ainsi qu’une amélioration d’autres symptômes de la TPILa TPI est un...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.